#!/usr/local/bin/php

Genital herpes cannot be cured and the virus-causing infection cannot be eliminated in the body. The need for other medications including vaccines for people infected with genital herpes is important to control and stop the virus from recurring. However, there are attempts to find the best vaccines for people infected with genital herpes, there are no perfect vaccine that prevents herpes infection. Researchers are working on vaccines for people infected with genital herpes; however some are on the experimental stage. These experimental vaccines seem to provide considerable protection to some people while hoping for an effective vaccine in the future.

Genital herpes is treated by antiviral medications against infections. These medicines are useful in shortening the amount of time or duration of an outbreak; prevent future attacks and alleviate the pain and discomfort caused by the sores, lesions, swollen glands and other body pains. These U.S. approved antiviral medications include: acyclovir (Zovirax), famciclovir (Famvir) and valacyclovir (Valtrex). These can only be taken with prescription from your doctor.

Vaccines for people infected with genital herpes are in the heights of development and in the area of active research. Several different approaches were clinically tested and tried on animals in the pursuit to find therapeutic vaccines for people infected with genital herpes. There is a therapeutic vaccine called AG-702, which is on the investigational stage at this time. This therapeutic vaccine for people infected with genital herpes is designed to induce a powerful T-cell immune response against a common viral antigen, making it an important advance over current therapies and earlier experimental genital herpes vaccines.

The development of an effective therapeutic vaccines for people infected with genital herpes is a good option for individuals with recurrent disease. It can cut cost of treatment and most and have a significant effect in decreasing the number of future outbreaks. As compared to the current treatments for genital herpes AG-702 is built on Antigenics’ HSP technology platform that can elicit a strong response from ‘killer’ T cells, which is considered to be critical for controlling infections. Antigenics is currently evaluating AG-702 in healthy volunteers and in patients with genital herpes. This Phase 1 trial is conducted at the University of Washington in Seattle (Herpes Center) to evaluate safety and immune response.

Ninety percent of cases of neonatal herpes were resulted from maternal-infant transmission. If vaccines for people infected with genital herpes especially pregnant mothers works perfectly, the virus could have possibly reduce the risk of maternal-infant transmission in pregnant women who experienced primary genital infection for the first time. The use of condoms will reduce the risk of infection during sexual contact but it is not 100 percent guaranteed. At this point, it’s not certain yet if these vaccines for people infected with genital herpes s have really made a difference, although in some people during research trials, the frequency of their attacks does seem to have improved. These vaccines for people infected with genital herpes are not generally available the public and further research and clinical tests are still on the works.